1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

UCB Pushes On With Potential Myasthenia Gravis Therapy, But Competition Looms

 
• By John Davis

The anti-FcRn MAb, rozanolixizumab, has been found to be effective in myasthenia gravis and has potential in ITP, but other companies are also developing potential therapeutic candidates for such auto-immune conditions.  

Acceleration
The development of rozanolixizumab is to be accelerated. • Source: Shutterstock

UCB SA is planning to start a confirmatory clinical study of its novel subcutaneously administered anti-FcRn antibody, rozanolixizumab, in the auto-immune disorder myasthenia gravis in the second half of 2019, after finding the MAb was associated with positive clinical benefits in a Phase II proof-of-concept study in the condition.

The Brussels, Belgium-based multinational is striving to best other companies keen to develop new therapies for myasthenia gravis, a condition...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Therapy Areas

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.